GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » EV-to-FCF

Hyloris Pharmaceuticals (XBRU:HYL) EV-to-FCF : -22.21 (As of Apr. 29, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hyloris Pharmaceuticals's Enterprise Value is €298.66 Mil. Hyloris Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-13.45 Mil. Therefore, Hyloris Pharmaceuticals's EV-to-FCF for today is -22.21.

The historical rank and industry rank for Hyloris Pharmaceuticals's EV-to-FCF or its related term are showing as below:

XBRU:HYL' s EV-to-FCF Range Over the Past 10 Years
Min: -60.65   Med: -27.7   Max: -18.34
Current: -22.21

During the past 8 years, the highest EV-to-FCF of Hyloris Pharmaceuticals was -18.34. The lowest was -60.65. And the median was -27.70.

XBRU:HYL's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 4.475 vs XBRU:HYL: -22.21

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Hyloris Pharmaceuticals's stock price is €11.70. Hyloris Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.563. Therefore, Hyloris Pharmaceuticals's PE Ratio for today is At Loss.


Hyloris Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Hyloris Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals EV-to-FCF Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - -36.48 -35.26 -20.28 -24.39

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.26 - -20.28 - -24.39

Competitive Comparison of Hyloris Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Hyloris Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's EV-to-FCF falls into.



Hyloris Pharmaceuticals EV-to-FCF Calculation

Hyloris Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=298.660/-13.449
=-22.21

Hyloris Pharmaceuticals's current Enterprise Value is €298.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-13.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hyloris Pharmaceuticals  (XBRU:HYL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hyloris Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=11.70/-0.563
=At Loss

Hyloris Pharmaceuticals's share price for today is €11.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.563.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Hyloris Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (XBRU:HYL) Headlines